Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXiaoyu LiuWZWeiyan Zheng

Discussion

Loading...

Member takes

Overview

Retrospective analysis demonstrated improved MRD negativity and overall survival in acute myeloid leukemia patients treated with low-dose decitabine and venetoclax, highlighting effective therapy.

Key Points

  • The combination of low-dose decitabine and venetoclax achieved MRD negativity in 63.4% of patients after one cycle.
  • Eighty percent of patients in the study attained composite complete remission, showcasing a significant treatment effect.
  • Retrospective analysis evaluated outcomes in 41 patients with acute myeloid leukemia ineligible for intensive chemotherapy.
  • Findings indicate that the low-dose regimen may enable better long-term survival rates in this patient population.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d388https://doi.org/10.1182/blood-2025-3449
View Full Paper
Ask AI
Bookmark
Share